Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 02, 2022 07:05 ET | uniQure Inc.
~ Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation ~~ U.S. and European pre-approval inspections of...
Adamis Pharmaceuticals logo
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
September 21, 2022 07:30 ET | Adamis Pharmaceuticals Corporation
Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo ...
Adamis Pharmaceuticals logo
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
September 12, 2022 16:05 ET | Adamis Pharmaceuticals Corporation
The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO,...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
July 29, 2022 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
June 01, 2022 08:00 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections
January 06, 2022 11:45 ET | Deinove
DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections The DSMB1 considered that the benefit/risk...
DEINOVE annonce l’avis favorable du DSMB pour la poursuite de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile
January 06, 2022 11:45 ET | Deinove
DEINOVE annonce l’avis favorable du DSMB pour la poursuite de l’essai clinique de Phase II de DNV3837 dans les infections à Clostridioïdes difficile Le DSMB1 a jugé que la balance bénéfice/risque de...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
November 02, 2021 07:05 ET | uniQure Inc.
~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02,...
Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
July 26, 2021 02:00 ET | Immunicum AB
Press Release 26 July 2021 Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study  -- Independent Data Safety and Monitoring Board (DSMB) issues...
Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien
July 26, 2021 02:00 ET | Immunicum AB
Press Release 26 July 2021  Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien -- Independent Data Safety and Monitoring Board (DSMB) har avgivit...